Estimated Costs and Long-term Outcomes of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System
Stephen B. Williams(Cedars-Sinai Medical Center), Stephen J. Freedland(Cedars-Sinai Medical Center)
Cited by 58
Related Papers
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
|JAMA Oncology|2019|302
Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013
|JAMA Network Open|2022|55
Racial differences in circulating mitochondria‐derived peptides may contribute to prostate cancer health disparities
|The Prostate|2022|11
New horizons in bladder cancer research
|Urologic Oncology Seminars and Original Investigations|2019|10